11 patents currently held
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Aug 2028. from the record
Of the 11 now held by other companies, 11 name MedImmune Limited as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Aug 2028
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2035 · High confidence
Also notable
Ends Aug 2028 · High confidence
Also notable
Ends Jul 2036 · High confidence
Pyrrolobenzodiazepine-Antibody Conjugates
US 9,931,414
The most cited patent in this portfolio, cited by 51 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2035.
Polynucleotides and Polypeptide Sequences Involved in Cancer
US 8,216,582
Cited by 39 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Pyrrolobenzodiazepine-Antibody Conjugates
US 10,780,096
The newest of the three, granted 2020. It anchors the portfolio to 2036, later than anything else here.
Formerly held, still cited
Notable
Ends Oct 2033 · High confidence
Cited by 50 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
now held by MedImmune Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4 to 18, 2027 · next Jan 4
- 1 fee due Sep 24, 2027The maintenance fee for Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof (US 10,597,450) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for ANTI-IL13R ALPHA2 Antibodies (US 11,976,122) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 19, 2026
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Polynucleotides and Polypeptide Sequences Involved in Cancer | 4 in force | to Mar 2032 |
| PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates | 2 in force | to May 2038 |
| Pyrrolobenzodiazepine-Antibody Conjugates (2021) | 1 in force | to Jun 2040 |
| Site-Specific Antibody-Drug Conjugates | 1 in force | to Mar 2037 |
| Pyrrolobenzodiazepine-Antibody Conjugates (2017) | 1 in force | to Jul 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,216,582 | Polynucleotides and Polypeptide Sequences Involved in Cancer In force · High confidence | In force | High confidence | |
| US 8,937,163 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof In force · High confidence | In force | High confidence | |
| US 9,393,302 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,597,450 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,690,918 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates In force · High confidence | In force | High confidence | |
| US 9,931,414 | Pyrrolobenzodiazepine-Antibody Conjugates In force · High confidence | In force | High confidence | |
| US 10,780,096 | Pyrrolobenzodiazepine-Antibody Conjugates In force · High confidence | In force | High confidence | |
| US 11,702,473 | Site-Specific Antibody-Drug Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 10,722,594 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates In force · High confidence | In force | High confidence | |
| US 11,484,606 | Pyrrolobenzodiazepine-Antibody Conjugates In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 11 patents in force now held by others · 11 patents ended · 9 applications pending · 26 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.